APA (7th ed.) Citation

U, L., U, L., U, S., EB, W., B, N., U, K., . . . M, B. (2025). Design and rationale of the VICTORION-Difference study: A phase 4 randomized, double-blind, placebo-controlled clinical trial to assess inclisiran's early efficacy, safety, tolerability, as well as its impact on quality of life in individuals with hypercholesterolemia. American heart journal, 289, 117. https://doi.org/10.1016/j.ahj.2025.05.014

Chicago Style (17th ed.) Citation

U, Landmesser, et al. "Design and Rationale of the VICTORION-Difference Study: A Phase 4 Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess Inclisiran's Early Efficacy, Safety, Tolerability, as Well as Its Impact on Quality of Life in Individuals with Hypercholesterolemia." American Heart Journal 289 (2025): 117. https://doi.org/10.1016/j.ahj.2025.05.014.

MLA (9th ed.) Citation

U, Landmesser, et al. "Design and Rationale of the VICTORION-Difference Study: A Phase 4 Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess Inclisiran's Early Efficacy, Safety, Tolerability, as Well as Its Impact on Quality of Life in Individuals with Hypercholesterolemia." American Heart Journal, vol. 289, 2025, p. 117, https://doi.org/10.1016/j.ahj.2025.05.014.